A higher BMI at the time of diagnosis has no effect on clinical outcomes for people with HER-2-positive breast cancer
In contrast with previous findings, a retrospective cohort study carried out in Italy has found no negative effect of body mass index (BMI) at the time of diagnosis on clinical outcomes for patients with HER-2-positive metastatic breast cancer.
Using data from 329 consecutive patients with HER-2-positive breast cancer attending one of 14 centres over a median three-year follow-up period, researchers examined the effect of BMI at diagnosis on clinical outcomes. The patients were grouped according to their initial BMI. Those with a BMI <25.0 were categorised as normal or underweight following World Health Organization classifications, and those with a BMI >25 were considered overweight or obese. There were no other significant differences in the patients' baseline demographic characteristics and they all received first-line trastuzumab-based therapy.
Median progression-free survival was 14.8 months in the BMI <25 study group and 15.7 months among the patients...
Want to read more?
Unlock full access to RCNi Plus today
Save over 50% on your first three months:
- Customisable clinical dashboard featuring 200+ topics
- Unlimited online access to all 10 RCNi Journals including Cancer Nursing Practice
- RCNi Learning featuring 180+ RCN accredited learning modules
- NMC-compliant RCNi Portfolio to build evidence for revalidation
- Personalised newsletters tailored to your interests